CSL (ASX:CSL) News Today: Earnings Guidance Cut as US Vaccination Decline Impacts Stock

CSL Limited (ASX:CSL), a global biotechnology leader known for its plasma therapies and vaccines, has recently reduced its earnings guidance. This move comes as US vaccination rates decline, greatly impacting the pharmaceutical giant’s financial outlook. Additionally, CSL has postponed the demerger of its Seqirus vaccine business, furthering investor concerns about the company’s future performance. CSL stock price has reacted, recording a decrease of 0.5% amidst these developments. Investors are closely monitoring the situation to understand its full implications on CSL’s growth potential.